Arcus Biosciences Inc (RCUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has a cash flow conversion efficiency ratio of -0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-138.00 Million) by net assets ($524.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Arcus Biosciences Inc for the company's overall valuation and market capitalisation.
Arcus Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arcus Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcus Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcus Biosciences Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Arcus Biosciences Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
-0.168x |
|
Fonciere Lyonnaise
PA:FLY
|
0.011x |
|
Huaxi Securities Co Ltd Class A
SHE:002926
|
0.113x |
|
Nanjing Tanker Corp
SHG:601975
|
0.041x |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
N/A |
|
CorVel Corp
NASDAQ:CRVL
|
0.122x |
|
CITIC Heavy Industries Co Ltd
SHG:601608
|
0.033x |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Arcus Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arcus Biosciences Inc from 2016 to 2025. View today's stock price for Arcus Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $631.00 Million | $-482.00 Million | -0.764x | -117.93% |
| 2024-12-31 | $485.00 Million | $-170.00 Million | -0.351x | +47.08% |
| 2023-12-31 | $462.00 Million | $-306.00 Million | -0.662x | -199.35% |
| 2022-12-31 | $657.00 Million | $438.00 Million | 0.667x | +318.98% |
| 2021-12-31 | $841.45 Million | $-256.17 Million | -0.304x | -237.56% |
| 2020-12-31 | $502.30 Million | $111.17 Million | 0.221x | +149.36% |
| 2019-12-31 | $163.84 Million | $-73.46 Million | -0.448x | -145.00% |
| 2018-12-31 | $234.94 Million | $-43.00 Million | -0.183x | -12.37% |
| 2017-12-31 | $153.87 Million | $-25.06 Million | -0.163x | -25.14% |
| 2016-12-31 | $99.46 Million | $-12.94 Million | -0.130x | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more